Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Autor: Luft, Alexander V., Karaseva, Nina A., Kowalyszyn, Rubén Dario, Hernandez, Carlos Alberto, Csoszi, Tibor, De Vita, Ferdinando, Pfeiffer, Per, Sugimoto, Naotoshi, Kocsis, Judit, Csilla, Andràs, Bodoky, Gyorgy, Garnica Jaliffe, Georgina, Protsenko, Svetlana, Madi, Ayman, Wojcik, Elzbieta, Brenner, Baruch, Folprecht, Gunnar, Sarosiek, Tomasz, Peltola, Katriina Johanna, Bono, Peter, Ayala, Hubert, Aprile, Giuseppe, Gerardo, Cardellino Giovanni, Huitzil Melendez, Fidel David, Falcone, Alfredo, Di Costanzo, Francesco, Tehfe, Moustapha, Mineur, Laurent, García Alfonso, Pilar, Obermannova, Radka, Senellart, Hélène, Petty, Russell, Samuel, Leslie, Acs, Peter Istvan, Hussein, Maen Abdelkarim, Nechaeva, Marina N., Erdkamp, F.L.G., Won, Elizabeth, Bendell, Johanna Chock, Gallego Plazas, Javier, Lorenzen, Sylvie, Melichar, Bohuslav, Escudero, Miguel Angel, Pezet, Denis, Phelip, Jean-Marc, Kaen, Diego Lucas, Reeves, James A. Jr, Longo Muñoz, Federico, Madhusudan, Srinivasan, Barone, Carlo, Fein, Luis Enrique, Gomez Villanueva, Angel, Hebbar, Mohamed, Prausova, Jana, Visa Turmo, Laura, Vidal Barrull, Joana, Yilmaz, Mette Karen Nytoft, Beny, Alex, Van Laarhoven, H.M.W., DiCarlo, Brian Anthony, Esaki, Taito, Fujitani, Kazumasa, Geboes, Karen, Geva, Ravit, Kadowaki, Shigenori, Leong, Stephen, Machida, Nozomu, Raj, Moses Sundar, Ramirez Godinez, Francisco Javier, Ruzsa, Agnes, Ford, Hugo, Lawler, William E., Maisey, Nicolas Robert, Petera, Jiri, Shacham-Shmueli, Einat, Sinapi, Isabelle, Yamaguchi, Kensei, Hara, Hiroki, Beck, Joseph Thaddeus, Błasińska-Morawiec, Maria, Villalobos Valencia, Ricardo, Alcindor, Thierry, Bajaj, Madhuri, Berry, Scott, Gomez, Christina Maria, Dammrich, Daniel, Patel, Ravindranath, Taieb, Julien, Ten Tije, A.J., Burkes, Ronald L., Cabanillas, Fernando, Firdaus, Irfan, Chua, Cynthia Coo, Hironaka, Shuichi, Hofheinz, Ralf-Dieter, Lim, Howard J., Nordsmark, Marianne, Piko, Bela, Verma, Udit, Wadsley, Jonathan, Yukisawa, Seigo, Gutiérrez Delgado, Francisco, Denlinger, Crystal S., Kallio, Raija, Pikiel, Joanna, Wojcik-Tomaszewska, Joanna, Brezden-Masley, Christine, Jang, Raymond Woo-Jun, Pribylova, Jana, Sakai, Daisuke, Bartoli, Maria Alejandra, Cats, A., Grootscholten, M.I., Dichmann, Robert Andrew, Hool, Hugo, Shaib, Walid, Tsuji, Akihito, Van den Eynde, Marc, Velez-Cortez, Hector, Asmis, Timothy R., Fuchs, Charles S ^*, Shitara, Kohei, Di Bartolomeo, Maria, Lonardi, Sara, Al-Batran, Salah-Eddin, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke, Mansoor, Wasat, Enzinger, Peter C, Gorbounova, Vera, Wainberg, Zev A, Hegewisch-Becker, Susanna, Ferry, David, Lin, Ji, Carlesi, Roberto, Das, Mayukh, Shah, Manish A

Publikováno v: In The Lancet Oncology March 2019 20(3):420-435

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Autor: Goetz MP; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Toi M; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Campone M; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Sohn J; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Paluch-Shimon S; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Huober J; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Park IH; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Trédan O; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Chen SC; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Manso L; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Freedman OC; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Garnica Jaliffe G; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Forrester T; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Frenzel M; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Barriga S; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Smith IC; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Bourayou N; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy., Di Leo A; Matthew P. Goetz, Mayo Clinic, Rochester, MN; Masakazu Toi, Kyoto University, Kyoto, Japan; Mario Campone, Institut de Cancerologie de l'Ouest, Angers Cedex; Olivier Trédan, Centre Léon Bérard, Lyon; Nawel Bourayou, Eli Lilly, Paris, France; Joohyuk Sohn, Yonsei Cancer Center, Seoul; In Hae Park, National Cancer Center, Goyangsi, South Korea; Shani Paluch-Shimon, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Jens Huober, University of Ulm, Ulm, Germany; Shin-Cheh Chen, Chang Gung University Medical College, Taipei, Taiwan; Luis Manso, Hospital Universitario 12 de Octubre; Susana Barriga, Eli Lilly, Madrid, Spain; Orit C. Freedman, Durham Regional Cancer Centre, Oshawa, Ontario, Canada; Georgina Garnica Jaliffe, Grupo Médico CAMINO S.C., Mexico City, Mexico; Tammy Forrester, Martin Frenzel, and Ian C. Smith, Eli Lilly, Indianapolis, IN; and Angelo Di Leo, Hospital of Prato, Prato, Italy.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Nov 10; Vol. 35 (32), pp. 3638-3646. Date of Electronic Publication: 2017 Oct 02.